
Risvutatug Rezetecan Shows Survival Gains in Relapsed Lung Cancer Trial
The B7-H3-directed antibody-drug conjugate risvutatug rezetecan has demonstrated a significant survival advantage over topotecan in patients with relapsed small-cell lung cancer. Presented at the IASLC 2026 World Conference on Lung Cancer, the ARTEMIS-008 trial results indicate a 54% reduction in the risk of death for treated participants.

























